Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
Video content above is prompted by the following:
- Let’s begin our discussion by highlighting recent advances in clinical research that have transformed our approach to initial treatment for transplant-eligible multiple myeloma. Please highlight promising emerging strategies that give hope for improved outcomes in the newly diagnosed transplant-eligible patient population.
- How have recent clinical trials and treatment strategies evolved in addressing the initial management of patients with transplant-eligible multiple myeloma, and what key outcomes are we seeing that may impact frontline therapeutic approaches?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
